Search Results Page

Search Results

1 - 10 of 36 (0.36 seconds)

Novartis Ag vs Union Of India & Ors on 1 April, 2013

33. This would also clearly constitute an abuse of the patenting system and curb legitimate manufacture and sale of such products in India, especially if most of the patents/inventions are not being worked. The effort to extend the monopoly beyond the permissible period of 20 years in this manner is contrary to law as held by the Supreme Court in Novartis AG v. Union of India, AIR 2013 SC 1311"
Supreme Court of India Cites 62 - Cited by 45 - A Alam - Full Document

F. Hoffmann-La Roche Ltd, Switzerland ... vs Cipla Ltd., Mumbai Central, Mumbai on 7 September, 2012

43. The learned counsels for the defendants submit that the plaintiff's Patent Term Extension application contains a positive affirmation that US'834 claims REGORAFENIB. Placing reliance on Novartis (supra) and Hoffman La Roche (supra), they submit that the statements made in a foreign jurisdiction are relevant to assess the scope of a purported invention. They submit that in view of Section 8(1) and 8(2) of the Act, these details should have been disclosed by the plaintiff in the prosecution of its application for the Suit Patent.
Delhi High Court Cites 68 - Cited by 65 - M Singh - Full Document

Novartis Ag & Anr. vs Natco Pharma Limited & Anr. on 13 December, 2021

43. The learned counsels for the defendants submit that the plaintiff's Patent Term Extension application contains a positive affirmation that US'834 claims REGORAFENIB. Placing reliance on Novartis (supra) and Hoffman La Roche (supra), they submit that the statements made in a foreign jurisdiction are relevant to assess the scope of a purported invention. They submit that in view of Section 8(1) and 8(2) of the Act, these details should have been disclosed by the plaintiff in the prosecution of its application for the Suit Patent.
Delhi High Court Cites 54 - Cited by 9 - C H Shankar - Full Document
1   2 3 4 Next